Utomilumab, previously known as PF-2566, represents a noteworthy innovative avenue in chronic disease . This humanized antibody uniquely blocks the process of CD16 – a critical receptor involved in antibody-dependent cellular cytotoxicity . Current research suggest promising efficacy in reducing the disease severity, especially within the context